ClinicalTrials.gg
CompletedNCT03021018Updated Dec 16, 2020Results posted

A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting

A Phase 2 interventional study of Brivaracetam and Lorazepam in Epilepsy, sponsored by UCB Biopharma S.P.R.L.. Completed at 14 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-12-16.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
24th of 34
46 · median 94
Started
2017
with 2 others
Phase 2
6 of 34
none open now
Registered
21st of 34
by date
Lead sponsor
3 of 34
UCB Biopharma S.P.R.L.

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 24th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 21st registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Epilepsy
  • Brivaracetam
  • Epilepsy Monitoring Unit
  • Increased seizure activity
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female, 18 to 70 years of age, inclusive
  • Subject has an established diagnosis of epilepsy
  • Subject has been admitted to the institution's Epilepsy Monitoring Unit (EMU) for seizure characterization or noninvasive presurgical evaluation or such admission is planned within 21 days of Screening

Exclusion criteria

Exclusion Criteria:

  • Subject has previously participated in this study and was treated with study drug. Re-screen is permitted
  • Subject has participated in another study of an medicinal product (IMP) or a medical device within the previous 30 days of Epilepsy Monitoring Unit (EMU) admission or is currently participating in another study of an IMP or a medical device
  • Subject has taken brivaracetam (BRV) in the 21 days prior to EMU admission
  • History or presence of status epilepticus during the 6 months prior to EMU admission
  • Subject has a medical or psychiatric condition that in the opinion of the Investigator could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has > 2x (ULN) of any of the following: , aspartate aminotransferase, alkaline phosphatase, or > ULN total
  • Subject has chronic liver disease
  • Subject has to BRV or any of its
  • Subject has a history of alcohol or drug abuse during the 6 months prior to EMU admission
  • Subject with a history of psychogenic seizures
  • Subject is a pregnant or lactating female
  • Subject has a history of a significant Adverse Event (AE) due to a benzodiazepine in the opinion of the Investigator
  • Subject has respiratory failure (or is at risk for respiratory failure), untreated sleep apnea, or other severe cardiorespiratory disease with Class III or IV functional status, or requires supplemental oxygen
  • Subject has acute narrow-angle glaucoma or myasthenia gravis
  • Subject is receiving benzodiazepine treatment (defined as an average of >=4 administrations per week) that started less than 28 days prior to EMU admission
  • Subject has a known allergic reaction or intolerance to benzodiazepines or benzodiazepine excipients
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Brivaracetam (BRV) 100 mg

    Two 5 ml vials of brivaracetam administered intravenously over a 2-minute period

    Drug: Brivaracetam

  • Experimental
    Brivaracetam (BRV) 200 mg

    Four 5 ml vials of brivaracetam administered intravenously over a 4-minute period

    Drug: Brivaracetam

  • Active comparator
    Lorazepam (LZP)

    Lorazepam bolus is to be injected based on information from the patient leaflet/package insert. The rate of injection should not exceed 2.0 mg/min. The LZP dose will be determined according to the Investigator's clinical judgment.

    Drug: Lorazepam

Interventions

  • * Pharmaceutical Form: Solution for infusion * Concentration: 10 mg/ml * Route of Administration: intravenous

    Also known as: Briviact

  • * Pharmaceutical Form: Solution for injection * Route of Administration: intravenous

06

What researchers measure

Primary outcomes

  1. Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication

    This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed with electroencephalogram \[EEG\] confirmation) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.

    Time frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)

Secondary outcomes

  1. Time to Next Seizure (Per Clinical Observation) or Rescue Medication

    This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed and not necessarily confirmed via electroencephalogram \[EEG\]) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.

    Time frame: During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)

  2. Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set multiplied by 100.

    Time frame: At 6 hours after the end of study drug administration

  3. Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.

    Time frame: At 8 hours after the end of study drug administration

  4. Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.

    Time frame: At 12 hours after the end of study drug administration

  5. Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set multiplied by 100.

    Time frame: During the 6 hours after the end of study drug administration

  6. Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.

    Time frame: During the 8 hours after the end of study drug administration

  7. Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration

    This variable was defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.

    Time frame: During the 12 hours after the end of study drug administration

07

Results

Posted May 28, 2019

Participant flow

The study started to enroll patients in February 2017 and concluded in April 2018.

Participant flow — Overall Study
MilestoneLorazepam (LZP)Brivaracetam (BRV) 100 mgBrivaracetam (BRV) 200 mg
Started161515
Completed141515
Not completed200
Withdrew: Adverse event100
Withdrew: Fall with subsequent nasal fracture100

Outcome measures

PrimaryTime to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication

This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed with electroencephalogram \[EEG\] confirmation) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.

Time frame:
During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)
Reported as:
Median · hours
Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue Medication
hoursLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Time to Next Seizure (Per Clinical Observation With Electroencephalogram [EEG] Confirmation) or Rescue MedicationNA (5.55 to NA)NA (6.93 to NA)NA (4.33 to NA)
SecondaryTime to Next Seizure (Per Clinical Observation) or Rescue Medication

This variable was calculated in hours. The event of next seizure was defined as the first seizure (clinically observed and not necessarily confirmed via electroencephalogram \[EEG\]) with the start date and time within 12 hours after the end of investigational medicinal product (IMP) administration.

Time frame:
During the Treatment Period (Day 1) until Safety Follow-Up Visit (Day 2)
Reported as:
Median · hours
Time to Next Seizure (Per Clinical Observation) or Rescue Medication
hoursLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Time to Next Seizure (Per Clinical Observation) or Rescue MedicationNA (5.55 to NA)NA (6.93 to NA)NA (4.33 to NA)
SecondaryPercentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects seizure free during 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat (ITT) set multiplied by 100.

Time frame:
At 6 hours after the end of study drug administration
Reported as:
Number · percentage of participants
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration
percentage of participantsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 6 Hours After the End of Study Drug Administration73.386.780.0
SecondaryPercentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects seizure free during 8 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.

Time frame:
At 8 hours after the end of study drug administration
Reported as:
Number · percentage of participants
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration
percentage of participantsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 8 Hours After the End of Study Drug Administration73.380.080.0
SecondaryPercentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects seizure free during 12 hours after the end of study drug administration divided by the number of subjects in the ITT set multiplied by 100.

Time frame:
At 12 hours after the end of study drug administration
Reported as:
Number · percentage of participants
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration
percentage of participantsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Are Seizure-free Per Clinical Observation at 12 Hours After the End of Study Drug Administration60.080.080.0
SecondaryPercentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects who received rescue medication with start date and time within the first 6 hours after the end of study drug administration divided by the number of subjects in the Intent-to-Treat as randomized (ITT-R) set multiplied by 100.

Time frame:
During the 6 hours after the end of study drug administration
Reported as:
Number · percentage of participnats
Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration
percentage of participnatsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Receive Rescue Medication During the 6 Hours After the End of Study Drug Administration20.006.7
SecondaryPercentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects who received rescue medication with start date and time within the first 8 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.

Time frame:
During the 8 hours after the end of study drug administration
Reported as:
Number · percentage of participants
Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration
percentage of participantsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Receive Rescue Medication During the 8 Hours After the End of Study Drug Administration26.76.713.3
SecondaryPercentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration

This variable was defined as the number of subjects who received rescue medication with start date and time within the first 12 hours after the end of study drug administration divided by the number of subjects in the ITT-R set multiplied by 100.

Time frame:
During the 12 hours after the end of study drug administration
Reported as:
Number · percentage of participnats
Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration
percentage of participnatsLorazepam (LZP) (ITT-R)Brivaracetam (BRV) 100 mg (ITT-R)Brivaracetam (BRV) 200 mg (ITT-R)
Percentage of Subjects Who Receive Rescue Medication During the 12 Hours After the End of Study Drug Administration40.06.713.3

Adverse events

Collected over From Screening, at Day -28 and up to Safety Follow-Up (24 hours after the end of drug administration).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lorazepam (LZP) (ITT-T)0/16 (0%)1/16 (6.3%)4/16 (25%)
Brivaracetam (BRV) 100 mg (ITT-T)0/15 (0%)0/15 (0%)6/15 (40%)
Brivaracetam (BRV) 200 mg (ITT-T)0/15 (0%)0/15 (0%)3/15 (20%)
Most frequent serious events
Most frequent serious events
EventLorazepam (LZP) (ITT-T)Brivaracetam (BRV) 100 mg (ITT-T)Brivaracetam (BRV) 200 mg (ITT-T)
Seizure clusterNervous system disorders1/160/150/15
Most frequent other events
Showing 10 of 16
Most frequent other events
EventLorazepam (LZP) (ITT-T)Brivaracetam (BRV) 100 mg (ITT-T)Brivaracetam (BRV) 200 mg (ITT-T)
DizzinessNervous system disorders0/163/151/15
NauseaGastrointestinal disorders0/162/152/15
HeadacheNervous system disorders1/162/150/15
SedationNervous system disorders2/160/151/15
SomnolenceNervous system disorders2/160/150/15
Atrioventricular dissociationCardiac disorders0/161/150/15
TachycardiaCardiac disorders0/161/150/15
VertigoEar and labyrinth disorders0/161/150/15
VomitingGastrointestinal disorders0/160/151/15
Vessel puncture site painGeneral disorders0/161/150/15

Baseline characteristics

Baseline Characteristics refer to the Intent-to-Treat as Treated Set which consisted of subjects who were treated with investigational medicinal product (IMP) regardless of qualifying seizure status.

Age, Categorical
Age, Categorical(Participants)Lorazepam (LZP)Brivaracetam (BRV) 100 mgBrivaracetam (BRV) 200 mgTotal Title
<=18 years0011
Between 18 and 65 years16141343
>=65 years0112
Age, Continuous
Age, Continuous(years)Lorazepam (LZP)Brivaracetam (BRV) 100 mgBrivaracetam (BRV) 200 mgTotal Title
Mean41.10 ± 11.1843.92 ± 12.4141.59 ± 15.9842.18 ± 13.06
Sex: Female, Male
Sex: Female, Male(Participants)Lorazepam (LZP)Brivaracetam (BRV) 100 mgBrivaracetam (BRV) 200 mgTotal Title
Female118423
Male571123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lorazepam (LZP)Brivaracetam (BRV) 100 mgBrivaracetam (BRV) 200 mgTotal Title
Asian0112
Black or African American4228
White12121236
08

Study locations

14 sites
  • Ep0087 108
    Birmingham, Alabama 35294, United States
  • Ep0087 117
    Tucson, Arizona 85724, United States
  • Ep0087 112
    Orlando, Florida 32806, United States
  • Ep0087 115
    Chicago, Illinois 60611, United States
  • Ep0087 113
    Chicago, Illinois 60612, United States
  • Ep0087 119
    Wichita, Kansas 67214, United States
  • Ep0087 116
    Belmont, Massachusetts 02478, United States
  • Ep0087 106
    Boston, Massachusetts 02215, United States
  • Ep0087 107
    Detroit, Michigan 48201, United States
  • Ep0087 125
    Lebanon, New Hampshire 03756, United States
  • Ep0087 120
    Rochester, New York 14642, United States
  • Ep0087 121
    Chapel Hill, North Carolina 27599, United States
  • Ep0087 105
    Charlotte, North Carolina 28204, United States
  • Ep0087 123
    Hershey, Pennsylvania 17033-2360, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Apr 2018, 14 months.

Results were first posted in May 2019, 1 year 1 month after primary completion.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 14 months is below that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2017
First posted
Jan 13, 2017
StartActual
Feb 6, 2017
Primary completionActual
Apr 27, 2018
CompletionActual
Apr 27, 2018
Results first posted
May 28, 2019
Last update
Dec 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03021018
Responsible party
Sponsor
First posted
Jan 13, 2017
Start date
Feb 6, 2017
Primary completion
Apr 27, 2018
Completion
Apr 27, 2018
Results posted
May 28, 2019
Last update
Dec 16, 2020

Study contacts

UCB Cares
study director · UCB (+1 844 599 2273)

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion